Literature DB >> 12576442

Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.

Jeremy J W Chen1, Pei-Li Yao, Ang Yuan, Tse-Ming Hong, Chia-Tung Shun, Min-Liang Kuo, Yung-Chie Lee, Pan-Chyr Yang.   

Abstract

PURPOSE: To evaluate the interaction between tumor-infiltrating macrophages and cancer cells and its effect on the expression of a potent angiogenic factor, interleukin-8 (IL-8), tumor angiogenesis, and patient outcome in non-small cell lung cancer (NSCLC). EXPERIMENTAL
DESIGN: We measured tumor IL-8 mRNA expression (by real-time quantitative reverse transcription-PCR), intratumor microvessel counts, and tumor-infiltrating macrophage density (by immunohistochemical staining) in 35 NSCLC surgical specimens and correlated with the patient's clinical outcome. We then investigated the interaction between macrophages (cell line THP-1) and six different human cancer cell lines (four NSCLCs, one osteosarcoma, and one hepatoma) and its effect on IL-8 mRNA expression using a macrophage/cancer cell coculture system, IL-8 mRNA expression in lung cancer cells, and macrophages being measured separately after coculture in the presence or absence of six anti-inflammatory agents, i.e., pentoxifylline, aspirin, indomethacin, dexamethasone, celecoxib (a selective cyclooxygenase-2 inhibitor), and pyrrolidine dithiocarbamate, a specific nuclear factor kappaB (NF-kappaB) inhibitor. NF-kappaB transcriptional activity and protein levels were measured by reporter gene assay and Western blot.
RESULTS: The tumor-infiltrating macrophage density correlated significantly and positively with tumor IL-8 mRNA expression and intratumor microvessel counts and significantly and negatively with patient survival. In addition, after cell-cell interaction in cancer cell:macrophage cocultures, marked IL-8 mRNA expression was induced in lung cancer cells (approximately 270-fold) and, to a lesser degree, in macrophages (4.5-fold). The increase in IL-8 mRNA expression correlated with the in vitro metastatic potential of the cancer cells. All six anti-inflammatory agents suppressed induction of IL-8 mRNA expression in lung cancer cells by >90%, four (pentoxifylline, celecoxib, pyrrolidine dithiocarbamate, and dexamethasone) having a dose-dependent effect. NF-kappaB transcriptional regulation and protein levels were simultaneously increased in the nuclei of cancer cells in macrophage/cancer cell cocultures, this effect also being suppressed by all six anti-inflammatory agents.
CONCLUSIONS: The interaction between infiltrating macrophages and cancer cells up-regulates IL-8 mRNA expression, especially in the cancer cells; this may contribute greatly to the increased tumor angiogenesis and adverse outcome in NSCLC patients with a high density of tumor-infiltrating macrophages. Anti-inflammatory agents can suppress the induction of IL-8 mRNA expression seen in lung cancer cells after coculture with macrophages, and this suppression is mediated, in part, through the NF-kappaB pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576442

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  113 in total

1.  Tumor-associated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery.

Authors:  Po-Hao Feng; Chih-Teng Yu; Chin-Yang Wu; Meng-Jung Lee; Wei-Hwa Lee; Liang-Shun Wang; Shu-Min Lin; Jen-Fen Fu; Kang-Yun Lee; Tzung-Hai Yen
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome.

Authors:  Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

3.  The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Authors:  Yong-Feng Yu; Zhi-Wei Chen; Zi-Ming Li; Zong-Hai Li; Shun Lu
Journal:  Curr Ther Res Clin Exp       Date:  2009-04

4.  Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC.

Authors:  S A Almatroodi; C F McDonald; I A Darby; D S Pouniotis
Journal:  Cancer Microenviron       Date:  2015-08-30

Review 5.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 6.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

7.  Alveolar macrophage function is altered in patients with lung cancer.

Authors:  D S Pouniotis; M Plebanski; V Apostolopoulos; C F McDonald
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

8.  Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.

Authors:  Keith D Eaton; Perrin E Romine; Gary E Goodman; Mark D Thornquist; Matt J Barnett; Effie W Petersdorf
Journal:  J Thorac Oncol       Date:  2018-03-23       Impact factor: 15.609

9.  Macrophage Infiltration in Tumor Stroma is Related to Tumor Cell Expression of CD163 in Colorectal Cancer.

Authors:  Ivan Shabo; Hans Olsson; Rihab Elkarim; Xiao-Feng Sun; Joar Svanvik
Journal:  Cancer Microenviron       Date:  2014-04-28

10.  IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.

Authors:  Irma Airoldi; Emma Di Carlo; Claudia Cocco; Emanuela Caci; Michele Cilli; Carlo Sorrentino; Gabriella Sozzi; Silvano Ferrini; Sandra Rosini; Giulia Bertolini; Mauro Truini; Francesco Grossi; Luis Juan Vicente Galietta; Domenico Ribatti; Vito Pistoia
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.